CERS2 (Ceramide Synthase 2), also known as Lass2, is a key enzyme in sphingolipid metabolism that catalyzes the synthesis of ceramide molecules with very-long-chain acyl groups (C20-C22). Ceramide serves as a central hub in sphingolipid metabolism, functioning both as a structural component of cell membranes and as a signaling molecule involved in numerous cellular processes including apoptosis, cell proliferation, and inflammation[1].
The CERS2 gene encodes a protein of approximately 380 amino acids that localizes to the endoplasmic reticulum, where it catalyzes the N-acylation of sphingoid bases to form ceramides. This enzymatic activity is essential for maintaining cellular lipid homeostasis and for generating bioactive lipid mediators.
| Property | Value |
|---|---|
| Gene Symbol | CERS2 |
| Full Name | Ceramide Synthase 2 |
| Aliases | Lass2, LASS2, TEGT |
| Chromosomal Location | 1q42.2 |
| NCBI Gene ID | 29956 |
| OMIM | 606922 |
| Ensembl ID | ENSG00000156599 |
| UniProt | Q9H0K0 |
The CERS2 protein contains several functional features:
The protein localizes primarily to the endoplasmic reticulum (ER), where it performs its catalytic function. CERS2 shows specificity for very-long-chain fatty acids (C20-C22), distinguishing it from other ceramide synthases (CERS1, CERS3-6) that prefer different chain lengths[2].
CERS2 catalyzes the following reaction:
Sphingosine + acyl-CoA → ceramide + CoA
This reaction represents a critical step in sphingolipid biosynthesis:
CERS2-derived ceramides contribute to membrane properties:
CERS2 plays dual roles in cell death decisions:
CERS2 shows tissue-specific expression:
In the brain, CERS2 expression is particularly notable in:
CERS2 has emerged as a significant factor in Huntington's disease[3]:
CERS2 involvement in Alzheimer's disease[4]:
Evidence for CERS2 in Parkinson's disease[5]:
CERS2 mutations associated with[6]:
CERS2-produced ceramides activate multiple signaling pathways[7]:
| Pathway | Effect | Disease Relevance |
|---|---|---|
| Ceramide-activated protein phosphatases | Pro-apoptotic | HD, AD |
| PKC isoforms | Cell survival | Cancer, neurodegeneration |
| JNK pathway | Stress response | PD, HD |
| p38 MAPK | Inflammation | Neuroinflammation |
CERS2 (Ceramide Synthase 2/Lass2) is an enzyme that catalyzes the synthesis of C20-C22 ceramides, playing critical roles in sphingolipid metabolism and cellular signaling. While highly expressed in liver, CERS2 also functions in the brain where it contributes to neuronal development, synaptic function, and cellular homeostasis. Dysregulated CERS2 activity and altered ceramide metabolism have been implicated in Alzheimer's disease, Parkinson's disease, and Huntington's disease. Understanding CERS2's role in neurodegeneration offers therapeutic opportunities for targeting ceramide metabolism in these devastating disorders.
CERS2-produced ceramides play a dual role in neuronal survival decisions. Under physiological conditions, basal ceramide levels support cell survival through activation of protein phosphatases PP1 and PP2A, which regulate various cellular processes including glycogen metabolism and protein synthesis[8]. However, excessive ceramide accumulation triggers the intrinsic apoptotic pathway through:
In Alzheimer's disease, amyloid-beta oligomers have been shown to upregulate CERS2 expression in neurons, leading to ceramide accumulation and subsequent apoptosis. This creates a vicious cycle where Aβ-induced neuronal death produces more ceramide, which in turn promotes further Aβ production through mechanisms involving APP processing[4:1].
CERS2 and its ceramide products significantly modulate neuroinflammatory responses[9]. Microglial activation states are influenced by:
CERS2 has direct effects on mitochondrial health:
In the central nervous system, CERS2 is essential for proper myelin formation and maintenance[10]. Oligodendrocytes are particularly dependent on CERS2-derived very-long-chain ceramides for:
Several approaches target CERS2 for therapeutic benefit:
| Compound | Mechanism | Development Status |
|---|---|---|
| FTY720 (Fingolimod) | Ceramide synthase modulator | Approved for MS, investigating for AD |
| L-aldotripeptide ceramide analogs | CERS2-specific activators | Preclinical |
| Myriocin | Serine palmitoyltransferase inhibitor | Preclinical |
| Fumonisin B1 | Ceramide synthase inhibitor | Research tool |
Viral vector-mediated CERS2 delivery represents a promising approach:
Rational combinations under investigation:
The aging brain shows progressive changes in CERS2 expression and function[11]:
Circulating and CSF biomarkers under investigation:
Biomarkers for patient selection:
Grosch S, Schiffmann S, Philipp U. Ceramide synthases in health and disease. Journal of Lipid Research. 2016. ↩︎
Wang Y, Liu J, Huang Z. Targeting ceramide metabolism for neuroprotection. Cellular and Molecular Life Sciences. 2021. ↩︎
Jazvin J, et al. CERS2 and Huntington's disease pathology. Neurobiology of Aging. 2017. ↩︎
Schneider M, et al. Ceramide species in Alzheimer's disease brain. Neurobiology of Aging. 2019. ↩︎ ↩︎
Jazbi A, et al. Targeting CERS2 for Parkinson's disease therapy. Movement Disorders. 2020. ↩︎
Tanaka R, et al. CERS2 mutations and metabolic disease. Diabetes. 2015. ↩︎
Spassieva S, Bielawski J, Liu J. Ceramide metabolism and neurodegenerative diseases. Cellular and Molecular Neurobiology. 2021. ↩︎
Meng X, et al. CERS2 in apoptosis and cell survival. Cell Death & Differentiation. 2018. ↩︎
Levy A, et al. CERS2 in neuroinflammation and glial activation. Brain, Behavior, and Immunity. 2020. ↩︎
Sassa T, et al. CERS2 and myelin formation in CNS. Journal of Neuropathology & Experimental Neurology. 2019. ↩︎
Park MH, et al. CERS2 in aging brain. Neurobiology of Aging. 2019. ↩︎